David J Goldberg, Chenwei Hu, Adam M Lubert, Rahul H Rathod, Daniel J Penny, Christopher J Petit, Kurt R Schumacher, Salil Ginde, Richard V Williams, J K Yoon, Gi Beom Kim, Todd T Nowlen, Michael V DiMaria, Benjamin P Frischhertz, Jonathan B Wagner, Kimberly E McHugh, Brian W McCrindle, Mark J Cartoski, Jon A Detterich, Anji T Yetman, Anitha S John, Marc E Richmond, Delphine Yung, R Mark Payne, Andrew S Mackie, Christopher K Davis, Shabana Shahanavaz, Kevin D Hill, Marisa Almaguer, Victor Zak, Michael G McBride, Bryan H Goldstein, Gail D Pearson, Stephen M Paridon
The Pediatric Heart Network's Fontan Udenafil Exercise Longitudinal (FUEL) Trial (Mezzion Pharma Co. Ltd., NCT02741115) demonstrated improvements in some measures of exercise capacity and in the myocardial performance index following 6 months of treatment with udenafil (87.5 mg twice daily). In this post hoc analysis, we evaluate whether subgroups within the population experienced a differential effect on exercise performance in response to treatment. The effect of udenafil on exercise was evaluated within subgroups defined by baseline characteristics, including peak oxygen consumption (VO2 ), serum brain-type natriuretic peptide level, weight, race, gender, and ventricular morphology...
June 29, 2023: Pediatric Cardiology